Abstract
In the fulminant VTE form with cardiac arrest, systemic thrombolysis remains the most effective therapy. However, several contraindications restrict the use such as intracranial neoplasm or a recent history of intracranial surgery. Here, we report the case of a 59-year-old man who underwent glioblastoma resection and suffered from a fulminant pulmonary embolism with cardiac arrest. After CPR, continuous tPA infusion via an endovascularly placed pulmonary catheter was maintained over a period of 8 h. In this case, we report on our decision-making process and the use of local thrombolysis as a successful therapy in a patient with multiple contraindications.
Similar content being viewed by others
Abbreviations
- LMWH:
-
Low molecular weight heparin
- VTE:
-
Venous thromboembolism
- ROSC:
-
Return of spontaneous circulation
- GBM:
-
Glioblastoma multiforme
- rtPA:
-
Recombinant tissue plasminogen activator
- 5-ALA:
-
5-aminolevulinic acid
References
Bayram B, Oray N, Korkmaz E, Erdost HA, Gokmen N (2014) Massive pulmonary embolism and cardiac arrest; thrombolytic therapy in a patient with recent intracranial surgery and glioblastoma multiforme. Am J Emerg Med 32(11):1441
Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV (1997) Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33(10):1592–1596
Chaichana KL, Pendleton C, Jackson C, Martinz-Gutierrez JC, Diaz-Stransky A, Aguayo J, Olivi A, Weingart J, Gallia G, Lim M, Brem H, Quinones-Hinojosa A (2013) Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res 35(2):206–211
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Heim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11(1):56–70
Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet (London, England) 353(9162):1386–1389
Han S (2006) Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor. J Intensive Care Med 21(4):240–245
Jenkins EO, Schiff D, Mackman N, Key NS (2010) Venous thromboembolism in malignant gliomas. J Thromb Haemost 8(2):221–227
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S
Lapner ST, Kearon C (2013) Diagnosis and management of pulmonary embolism. BMJ 346:f757
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kauder NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490–5505
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine HA, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189–2204
Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, Marosi C (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9(2):89–95
Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG (2004) ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 100(8):1717–1723
Streiff MB, Ye X, Kickler TS, Desideri S, Jani J, Fisher J, Grossmann SA (2015) A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol 124(2):299–305
Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, Bengel F, Brady AJB, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29(18):2276–2315
Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS (2015) Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 124(1):87–94
Acknowledgments
This study was possible only due to the interdisciplinary work performed by the staff of the Goethe University Hospital Frankfurt. DD provided clinical care to the patient and wrote and edited the manuscript. S-YW, MB, and M-TF provided clinical care to the patient. CS provided clinical assessment and supervised the manuscript. JB was involved in diagnostic and patient treatment. VS performed the operation and provided critical supervision of the manuscript and the study. JM provided clinical care to the patient and edited and directed the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Funding
No funding was received for this research.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Comments
The authors report a successful outcome after a PE-related cardiac arrest and subsequent treatment with intra-pulmonary artery lysis therapy with recombinant tissue plasminogen activator (rtPA), this all occurring only 24 h after a craniotomy and debulking of a left temporal lobe GBM.
Whilst the authors are to be congratulated on the high level of care offered in such an acute setting, this case does raise other issues, with perhaps a more likely outcome (if the patient survived at all) of significant neurological disability as a result of hemorrhage into the tumor resection bed. Is perhaps the paucity of reports of successfully treated patients in the literature is a reflection of this more likely outcome?
Most surgeons would undoubtedly have tried to resuscitate their patient given similar circumstances, but would most patients want such treatment if they knew the risks associated with the acute treatment and the natural history of GBM? Unfortunately, due to the acute way that most patients with GBM present, it is unlikely that they or their families are truly in a position to consent to anything but the primary procedure.
Paul Chumas
Leeds, UK
Dubinski and colleagues report an interesting case of successful selective pulmonary artery lysis therapy of a 59-year-old patient suffering from "cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection". This is especially interesting, since this lysis therapy has been used off-label. However, without this off-label use the patient would have died in all likelihood. This case report should also encourage other authors who may have performed off-label therapy in cases their patients would otherwise have died to publish their cases in order to give the readers inspiration on the one hand and to provide arguments in case of medicolegal difficulties.
Marcus Reinges
Giessen, Germany
Rights and permissions
About this article
Cite this article
Dubinski, D., Won, SY., Bruder, M. et al. Decision-making in a patient with cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection. Acta Neurochir 158, 2259–2263 (2016). https://doi.org/10.1007/s00701-016-2982-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00701-016-2982-2